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Introduction
Affordability is not an unequivocal concept; Bradley1 calls it 
vague, and Whitehead,2 Milne3 and Komives et al.4 deny that 
it has a clear basis in economic theory. The theory assumes 
that a household chooses the bundle of goods and services 
that maximizes utility – i.e. the benefit derived per money 
spent – subject to its preferences and budget. Clearly, different 
preferences lead to different choices on how much to spend 
on a particular commodity. The definition of what constitutes 
an “affordable” price is thus a normative one that, according 
to some, lacks an economic foundation.5 A commodity is 
obviously unaffordable if it costs more than what is in the full 
(potential) budget, but such a definition is overly restrictive.
According to Maclennan & Williams, affordability has to 
do with securing a standard of living (e.g. housing, education 
or transport) at a price that “does not impose, in the eyes of 
a third party (usually government), an unreasonable burden 
on household incomes”.6 To operationalize the concept of 
affordability, one therefore needs: (i) information on house-
hold incomes; (ii) knowledge of the price of the commodity 
in question, and (iii) a definition of “unreasonable burden”. 
This highlights two problems related to measuring unafford-
ability. First, there is arbitrariness in defining “an unreasonable 
burden”. Previous work has identified two ways to define this 
unreasonable burden: (i) the so-called catastrophic payment 
method, which is based upon the ratio of the payment for a 
particular commodity to a household’s total resources, and 
(ii) the impoverishment method, which looks at a household’s 
residual income after paying for a good.2,5–8 The second prob-
lem is that to measure affordability in practice requires a large 
amount of household level data that is often difficult to access, 
only available for certain years, not comparable across different 
time periods or countries, or simply lacking.
To address the second problem while simultaneously 
acknowledging the first, in this paper we apply the impover-
ishment and catastrophic payment methods in a manner that 
can be applied to a broad range of commodities when micro 
data are scarce. We do this by applying these methods using 
widely available aggregate data, which makes for easy imple-
mentation and comparison across countries. We explore their 
use in elucidating the affordability of medicines, a commodity 
critically related to affordability. Indeed, in the developing 
world, medicines account for a substantial part of health-care 
costs.9–12 Since most of the population in many low-income 
countries lacks health insurance,13 medicines have to be paid 
for out-of-pocket when people fall ill. If their prices are too 
high, people are unable to procure them and often forego 
treatment altogether or get into debt.14 It is therefore important 
to examine and compare the affordability of medicines across 
countries in the developing world and to monitor the impact 
of interventions seeking to improve it.
Measuring affordability
As explained before, two approaches are generally used to 
estimate affordability. One relies on the ratio of expenditures to 
total household resources, whereas the second focuses on the 
residual income after an expenditure. Under the first approach, 
the payment for a commodity is deemed “catastrophic” (unaf-
fordable) when it exceeds a certain proportion of a household’s 
resources. The idea is that if a household spends a large fraction 
of its available budget on a specific item, it will have to reduce 
its consumption of other goods and services. The affordability 
threshold is subjective.4,5,15 Studies of this approach, which 
have focused primarily on the affordability of transportation,8 
education,16 health care15,17 and utilities such as energy and wa-
ter,18,19 define the affordability of a commodity in terms of the 
share of available resources that it consumes. Since spending 
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even a small share of the budget can have 
catastrophic consequences for very poor 
individuals, it makes sense to define af-
fordability in terms of the share of the 
budget that is left after spending on basic 
necessities (usually food). The latter has 
been referred to as “nondiscretionary 
expenditure” or “capacity to pay”.15,17
The second or “impoverishment” 
method considers the absolute quantity 
of available resources before and after 
payment for a commodity. If the house-
hold is initially above the poverty line 
but drops below it after paying for the 
commodity, it can be said to have been 
“impoverished” by the payment.7,15,17,20 
This approach has been commonly used 
to study housing affordability5,7 and 
has also been applied to health care.15,17 
Niëns et al. have recently calculated the 
affordability of medicines in 16 low- and 
middle-income countries using this im-
poverishment method.21 The method is 
clearly more specifically focused on the 
poor within society, as the closer you 
are to the poverty line, the more likely 
it is that certain expenditures will push 
you below it.
The methods as operationalized 
by Xu et al.15 and van Doorslaer et al.,11 
while theoretically optimal, may be dif-
ficult to apply in practice, especially in 
low- and middle-income countries, be-
cause they are relatively data intensive. 
This is particularly so if the goal is to 
monitor outcomes over time and make 
cross-country comparisons. Compari-
sons across countries and over time are 
further complicated by the fact that in-
dividual household surveys suffer from 
methodological heterogeneity.
Aware of the problems inherent 
in measuring affordability, the World 
Health Organization (WHO) and 
Health Action International (HAI) 
have used the wage of the lowest paid 
unskilled government worker (LPGW) 
to calculate the affordability of medi-
cines.12,22 Such affordability has been 
expressed in terms of the number of 
days the LPGW has to work to be able 
to pay for a course of treatment with 
a particular drug. This LPGW-based 
metric is easy to apply and to under-
stand; people in any country can eas-
ily position themselves relative to the 
LPGW. However, this metric may over-
estimate the affordability of medicines 
because a substantial proportion of the 
population in some countries earns less 
than the LPGW.12,21,23 Furthermore, the 
number of days of LPGW wages that 
makes something unaffordable is not 
clearly determined; this income metric 
is used only by WHO/HAI and no refer-
ence standards are available in the liter-
ature. As a result, the quest for a feasible 
way of applying the catastrophic and 
impoverishment methods in data-poor 
countries is amply justified.
In the remainder of this paper, we 
explain the methodological details of a 
less data-demanding and easily applica-
ble operationalization of the catastrophic 
and impoverishment methods, and we 
illustrate them by calculating the afford-
ability of glibenclamide, a drug for dia-
betes. For this purpose we have used data 
from a price survey undertaken with the 
WHO/HAI price measurement tool in 
India and Indonesia.22 We then compare 
the results of applying this method with 
the results of theoretically similar calcu-
lations using household data.
Methods
Throughout this paper we refer to 
household level data as micro data and 
to aggregated data as macro data. The 
methods proposed in this paper only re-
quire aggregated data and are therefore 
referred to as macro methods, whereas 
methods typically calling for micro 
data are referred to as micro methods. 
To check the sensitivity of our proposed 
method to using different data, we pro-
duce results for several combinations of 
data and methods.
Micro and macro methods
O’Donnell et al. elaborately explain 
how to calculate impoverishment and 
catastrophic spending at the household 
level using micro data.24 Other applica-
tions can be found in van Doorslaer et 
al.,11 Xu,15 Wagstaff & van Doorslaer17 
and Russell.25
The method for calculating medi-
cine affordability that we propose in this 
paper requires a knowledge of four com-
ponents: (i) the price of (treatment with) 
a given medicine (P) (ii) a country’s 
total population (Pop); (iii) the aggre-
gate income level of a country (Y); and 
(iv) the proportion of the total income 
earned across income groups (D) within 
a country. The last three components 
are first combined to draw an income 
distribution that plots the average daily 
income for each income group.  Fig. 1 
shows an example of such a distribution. 
The x-axis ranks the total population 
(Pop) by increasing income (income 
groups D1 to D7), whereas the y-axis plots 
the average daily incomes (groups Y1 to 
Y7). Because aggregated data are usually 
available for up to seven income groups, 
the explanation of our methods is based 
on this number, but the methods can be 
applied to more groups. 
Since we have no information on 
how income is distributed within each 
income group, we assume linearity and 
plot the average income of each group 
at the midpoint, i.e. we assume that 
the mean and median incomes in each 
income group coincide. For example, 
Fig. 1. Distribution of average daily per capita income across income groups in 
Indonesia (2005)
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for the income group between the 40th 
and 60th percentiles we plot the average 
income on the 50th percentile. This is 
clearly a simplification. In reality, the 
income distribution within each income 
group is likely to be skewed because 
most people in the group probably 
earn less than the average. This means 
that we are likely to overestimate the 
average income for each income group 
and therefore to underestimate the af-
fordability of the medicine later on in 
the analysis.
The impoverishment approach
This method aims to compare the pro-
portion of the population below the 
poverty line (PL) before (Ipre) and after 
(Ipost) the hypothetical procurement of a 
medicine. Assume that line PL in  Fig. 1 
represents the poverty line in a specific 
country. To calculate the proportion of 
the population living below this line, 
we focus on the income distribution 
between two income points, one just 
below and the other just above the 
poverty line, in this case A and B. With 
the coordinates of these points known, 
i.e. for A, (D1,Y1); for B, (D2,Y2), we can 
calculate the linear function of the (thick 
black) line going through A and B:
         
Y
Y Y
D D
D C=
−
−
+2 1
2 1  
(1)
which allows us to estimate the propor-
tion of the population living below the 
poverty line (Ipre).
To estimate the proportion of the 
population below the poverty line after 
purchasing a medicine, Ipost, we assume 
a parallel shift downwards of the linear 
function equal to the medicine price P. 
Equation 1 then changes into:
 
Y
Y Y
D D
D C P=
−
−
+ −2 1
2 1
′
 
(2)
Again, substituting Y ′ by PL in this 
Equation 2 gives us Ipost, the proportion 
of the population in poverty after pro-
curement of the medicine. The differ-
ence in the proportion of the population 
below the PL before and after paying 
P, Ipost − Ipre, gives the proportion of the 
population that would be impoverished 
if everyone had to buy a medicine cost-
ing P. For the percentage of the popula-
tion represented by Ipost, the medicine is 
deemed unaffordable.
The catastrophic approach
In the existing literature, total health 
care expenditures are usually consid-
ered catastrophic if they exceed 10% of 
a household’s total spending or 40% of 
non-food spending.15,17,24,26–28
In developing countries, such 
as India and Indonesia, medicines 
make up a relatively large portion 
(20–70%) of total health expenditure 
and are paid largely out-of-pocket.9–11 
According to data from WHO’s 2003 
World Health Survey for India, drug 
spending in the country accounts for 
about 44% of all out-of-pocket spend-
ing on health. Low health insurance 
coverage in Indonesia (26.1% in 2007) 
and India (approx 20%) indicate that 
most spending on medicines is paid 
for out-of-pocket.29,30
Hence, to calculate the afford-
ability of medicines we propose using 
a threshold that is roughly half the 
threshold generally used when calculat-
ing total health care expenditure (i.e. 5% 
instead of 10%). However, the method 
can obviously accommodate different 
percentages.
The proportion of the population 
for which purchasing a medicine costing 
P is catastrophic is again calculated from 
Fig. 1. At a 5% catastrophic threshold, 
the medicine with price P is unaffordable 
for people earning less than 20 times P. 
This proportion is again calculated by 
drawing a line between the points for 
average income that include 20P. By 
substituting Y by 20P in  Equation 1, we 
get the proportion of the population ex-
posed to catastrophic expenditure, Xcat.
Data sources
We obtained medicine prices from the 
WHO/HAI database, which lists median 
treatment prices for a large range of 
medicines. WHO/HAI collects medi-
cine prices from five medicine outlets 
per sector in at least four geographic or 
administrative regions in a given survey 
area. For each medicine, prices are col-
lected for both the originator brand and 
the lowest-priced generic equivalents in 
the private and public sectors. We use 
private sector prices because drug avail-
ability in the public sector is low and 
the data are often insufficient to make 
reliable price estimates.12,21
In our examples we use the price 
of 5 mg capsules/tablets of the lowest-
priced generic (LPG) glibenclamide in 
India (April 2003–January 2005) and 
Indonesia (August 2004) and assume the 
standard treatment regimen of 2 tablets 
a day. We chose these two countries be-
cause of the availability of micro, macro 
and medicine price data. We selected 
glibenclamide because in India and 
Indonesia diabetes affects 6.9 million 
and 50.7 million people (4.6% and 7.1% 
prevalence, respectively).31
When the lowest-priced generic 
equivalent of glibenclamide is procured 
in the Indonesian private sector, the 
median price of treatment with the drug 
is 417 Indonesian rupiah (IDR) a day. 
For India, seven WHO/HAI surveys 
are available, and each covers a state 
or part of a state. As the price of LPG 
glibenclamide in the private sector var-
ies little (between 1.28 and 1.60 Indian 
rupees (INR) a day) and given the aim 
of this paper, we work with the average 
price of LPG glibenclamide over the 
seven surveys, i.e. INR 1.40.
The aggregate income level (Y) 
and income distribution of India and 
Indonesia are retrieved from the World 
Bank’s World Development Indicators 
(WDIs). Gross domestic product (GDP) 
per capita is often used as a proxy for 
people’s actual incomes. However, a 
country’s GDP consists of consumption, 
gross investment, government spending 
and net trade. For this study the main 
interest lies in consumption, since it 
reflects the amount of money people 
can actually spend. Therefore, house-
hold final consumption expenditure as 
provided in the WDIs, is used. This is in 
line with micro-level analysis, in which 
expenditure data are usually preferred 
to income data because the former are 
believed to better reflect household 
resources in developing countries.24 As 
for income distribution D, the WDIs 
provide the percentage of total income 
earned in seven income groups: five 
quintiles, with the upper and lower 
quintiles split into two deciles each. 
We use the 2005 PL thresholds 
of 1.25 and 2.00 United States dollars 
(US$) a day, as suggested by the World 
Bank.32,33 We convert the PL thresholds 
to 2005 Indonesian rupiahs (IDR 4917 
and IDR 7869) and 2000 Indian rupees 
(INR 18.20 and INR 29.12) with con-
version factors from the World Bank 
International Comparison Program.34 
We perform all calculations of Ipre, 
Bull World Health Organ 2012;90:219–227 | doi:10.2471/BLT.10.084087222
Research
Measuring medicine affordability LM Niëns et al.
Ipost − Ipre and Xcat in local currency units, 
but we express all prices and amounts 
in this paper in 2005 purchasing power 
parity US$.
To check the robustness of our 
results, we also calculate the afford-
ability of LPG glibenclamide using 
micro data from the 2005 wave of the 
Indonesian National Socioeconomic 
Survey (Susenas) (n = 7302 households) 
and the Indian National Sample Survey 
(NSS) data set from 2000 (round 55) 
(n = 93 854 households). These surveys 
collect information on total household 
expenditures through an extensive 
expenditure module in the household 
survey.35,36
Results
Micro data
Table 1 shows the results of the calcula-
tions based on micro data. In Indonesia 
the proportions of the population living 
below the US$ 1.25 and US$ 2.00 PLs 
(Ipre) are 28.8% and 61.7%, respectively. 
The proportions of the population at 
risk of being impoverished by procuring 
LPG glibenclamide (Ipost − Ipre) are 5.8% 
and 3.7%, respectively. The catastrophic 
approach shows the proportion at risk 
of being confronted with catastrophic 
expenditures (Xcat) to be 65.9%.
In India, the proportion of people 
living below the US$ 1.25 and US$ 2.00 
PLs (Ipre) is 53.0% and 80.4%, respective-
ly. The impoverishment rates (Ipost − Ipre) 
in the country are 5.1% and 1.9%, and 
the proportion of the population at risk 
of catastrophic payments (Xcat) is 78.6%.
Macro data
Table 2 shows the results of using the 
aggregate income, as measured by 
the household final consumption ex-
penditure (Y), the proportion of total 
income earned across income groups 
(D) and the total population (Pop) to 
calculate the daily average income per 
capita for each income group in India 
and Indonesia. 
Dividing Y by Pop to derive per 
capita income estimates relies on the 
assumption that the average household 
size is constant across income groups. 
Since poorer households are typically 
larger,37 the average income per capita 
is likely to be overestimated in the 
lower income distribution ranges, which 
should make our affordability estimates 
conservative.
In Indonesia, the daily cost of 
the standard treatment with LPG 
glibenclamide is US$ 0.11, so indi-
viduals earning between US$ 1.25 
and US$ 1 .35  and between IDR 
US$ 2.00 and US$ 2.10 are at risk of 
being pushed below the US$ 1.25 and 
US$ 2.00 PLs, respectively, should they 
have to buy glibenclamide. In India, 
where the cost of LPG glibenclamide 
is US$ 0.10, the individuals at risk of 
being pushed below the US$ 1.25 and 
US$ 2.00 PLs are those whose income 
ranges between US$ 1.25 and US$ 1.34 
and between US$ 2.00 and US$ 2.09, 
respectively.
Table 1. Percentage of population impoverished or at risk of incurring catastrophic expenditure by purchasing treatment with lowest-
priced generic equivalent of glibenclamide, by micro method using micro data for India and Indonesia
Country (source) Population (%) below PL before medicine 
purchase (Ipre)
Population (%) impoverished by medicine 
purchase (Ipost − Ipre)
a
Catastrophic  
expenditure (Xcat)
b
< US$ 1.25c PL < US$ 2.00c PL < US$ 1.25c PL < US$ 2.00c PL
Indonesia (WDI 2005) 28.8 61.7 5.8 3.7 65.9
India (WDI 2000) 53.0 80.4 5.1 1.9 78.6
Ipost, percentage of the population below the poverty line (PL) after expenditure; Ipre, percentage of the population below the PL before expenditure; WDI, world 
development indicators (World Bank); Xcat, percentage of the population at risk of incurring a catastrophic expenditure at a threshold of 5% of per capita household 
expenditures.
a Impoverishment method.
b Catastrophic expenditure method.
c Purchasing power parity United States dollars (2005).
Table 2. Use of aggregated incomea and population data to calculate average daily income per capita (IPC) in specific income groups in 
India and Indonesia
Cumulative % of 
populationb
Income group India (WDI 2000) Indonesia (WDI 2005)
Income distribution 
(%)
Average daily IPC 
(INRc)
Income distribution 
(%)
Average daily IPC 
(IDRd)
D1 0–10 Poorest 10% 3.64 13.21 3.00 6 649
D2 10–20 Second poorest 10% 4.44 16.11 4.15 9 209
D3 20–40 Second 20% 11.27 20.45 10.74 11 914
D4 40–60 Third 20% 14.94 27.11 14.38 15 949
D5 60–80 Fourth 20% 20.37 36.96 20.45 22 683
D6 80–90 Second richest 10% 14.21 51.56 14.96 33 172
D7 90–100 Richest 10% 31.13 112.96 32.32 71 679
IDR, Indonesian rupiah; INR, Indian rupee; WDI, world development indicators (World Bank).
a In 2005 purchasing power parity United States dollars, aggregate income level (Y) for Indonesia is $425 869 484 516; Y for India is $1 046 538 703 424.
b Population of India in 2000: 1 015 923 000; population of Indonesia in 2005: 220 558 000.
c 1 US$ = 3934 INR.
d 1 US$ = 14.56 IDR.
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Table 3 shows the results of calcu-
lations based on macro methods and 
macro data. The differences are graphi-
cally presented in  Fig. 2. For India, the 
figure displays the two poverty lines and 
the average daily incomes per capita 
based on the macro and micro data and 
methods. The proportions of the popula-
tion below the US$ 2.00 PL are indicated 
with vertical lines from both the square 
and the triangle.
There are large differences between 
Ipre poverty estimates and World Bank 
WDIs. For Indonesia, the World Bank’s 
poverty estimates for 2006 are 28.04% 
(US$ 1.25 PL) and 62.76% (US$ 2.00 
PL), whereas for India (2005) they 
are 41.6% (US$ 1.25 PL) and 75.6% 
(US$ 2.00 PL).33 These estimates closely 
resemble the figures obtained using the 
micro method and micro data (Table 1), 
but not the ones (Ipre) obtained using the 
macro method and macro data (Table 3).
For each PL in Indonesia, the 
proportion of the population impover-
ished by the purchase of glibenclamide 
(Ipost − Ipre) is lower when calculated with 
the macro method and data (US$ 1.25 
PL: 0.0%; US$ 2.00 PL: 1.6%;  Table 3) 
than when calculated with the micro 
method and data (US$ 1.25 PL: 5.8%; 
US$ 2.00 PL: 3.7%;  Table 1). In India, 
the proportion impoverished (Ipost − Ipre) 
is lower only for the US$ 1.25 PL (4.8% 
in  Table 3 versus 5.1% in  Table 1), not 
for the US$ 2.00 PL (2.8% in  Table 3 
versus 1.9% in  Table 1). This is because 
in India the US$ 2.00 PL, here measured 
with the macro methods, is now located 
in a lower income region (the region 
marked with a square in  Fig. 2) where 
D is less skewed (i.e. compared with 
the region marked with a triangle in 
Fig. 2). In other words, the linear line 
in the region marked with a square is 
slightly flatter than the convex income 
distribution (D) in the region marked 
with a triangle, which causes the shift 
over D to be larger for the same parallel 
drop of the linear function.
In both countries, the propor-
tion of the population at risk of being 
confronted with catastrophic spend-
ing by purchasing glibenclamide (Xcat) 
differs substantially when calculated 
with the micro and macro approaches. 
While with the former, the proportion 
is 65.9% for Indonesia and 78.6% for 
India (Table 1), the latter approach 
gives proportions of 11.6% and 51.8% 
respectively (Table 3).
The results so far illustrate that the 
affordability of treatment with gliben-
clamide in India and Indonesia varies 
markedly depending on the method 
used to calculate it, but both the micro 
and macro approaches show that its 
affordability poses problems in both 
countries. The differences in the results 
obtained with the two methods may 
reflect a methodological effect or a data 
effect. We investigated this in more detail 
and found that while the methodological 
effect is negligible, the data effect is real, 
i.e. differences in micro and macro data 
account for the differences in the results 
found (Appendix A, available at: http://
repub.eur.nl/res/pub/30779).
Discussion
The issue of affordability is not straight-
forward. Although it is a rather norma-
tive concept,5 this paper has explored 
two methods for estimating the afford-
Table 3. Pecentage of population impoverished by or at risk of incurring catastrophic expenditure by purchasing treatment with lowest-
priced generic equivalent of glibenclamide, by macro method using macro data for India and Indonesia
Country (year) Population (%) below PL before  
medicine purchase (Ipre)
Population (%) impoverished by  
medicine purchase (Ipost − Ipre)
a
Catastrophic  
expenditure (Xcat)
b
< US$ 1.25c PL < US$ 2.00c PL < US$ 1.25c PL < US$ 2.00c PL
Indonesia (2005) 0.0 9.8 0.0 1.6 11.6
India (2000) 22.2 54.1 4.8 2.8 51.8
Ipost, percentage of the population below the poverty line (PL) after expenditure; Ipre, percentage of the population below the PL before expenditure; Xcat, percentage of 
the population at risk of incurring a catastrophic expenditure at a threshold of 5% of per capita household expenditures
a Impoverishment method.
b Catastrophic expenditure method.
c Purchasing power parity United States dollars (2005).
Fig. 2. Poverty lines and incomes for India based on macro and micro data and methods
Y micro data 1.25 US$ PL Y macro data 2.00 US$ PL
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(2005).
Note: The x-axis lists the middle of the income group percentiles used with the macro approach to plot 
our graph. As such, the graph based on macro data begins and ends at the 5th and 95th percentiles, 
respectively. The proportions of the population below the US$ 2.00 PL are indicated with vertical lines 
from both the square and the triangle.
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ability of medicines in low- and middle-
income countries: the catastrophic and 
the impoverishment method. To ensure 
their practical applicability, both were 
designed for use with aggregated data on 
medicine prices, per capita income level, 
and income distribution that are easily 
available for a broad set of developing 
countries from the WDIs and the WHO/
HAI medicine price database. This facili-
tates the measurement, comparison and 
monitoring of affordability in a range 
of countries over time, as illustrated by 
Niëns et al.21 Clearly, the use of aggregat-
ed data does require some simplifying 
assumptions. For instance, in our study 
we have conservatively assumed per 
capita income to be linearly distributed 
across income groups, which is likely to 
generate bias and lead to lower afford-
ability results. Other assumptions can 
be made in a relatively straightforward 
manner (e.g. by fitting a distribution line 
to the observed points). Worthy of note 
is that the methods presented here as-
sess the catastrophic and impoverishing 
effects of hypothetical expenditures on 
medicines. In this setting, a medicine is 
considered 100% affordable if everyone 
can procure it without experiencing 
financial hardship.
This study has some limitations. 
First, the usefulness of the proposed 
aggregated method depends largely on 
the validity of the aggregated income 
data. We found the WDI’s household 
final consumption expenditure esti-
mates to be substantially higher than 
the income data collected in household 
surveys, a finding in line with Raval-
lion’s observation that income data from 
household surveys for 88 countries with 
national accounts were lower 77% of the 
time.38 Thus, the use of macro methods 
leads to impoverishment rates that are 
lower than expected most of the time. 
Although household survey data gener-
ally yield the most precise estimates of 
affordability, total expenditure estimates 
from household surveys also differ be-
cause of differences in survey structure 
and in the questions asked.39,40
A more general limitation of our 
study is that it focuses on the afford-
ability of a single medicine, which ob-
viously ignores the need for more than 
one medicine and for other therapeutic 
methods in some cases, as well as related 
costs, such as fees for physician visits. 
However, our objective was not to pro-
vide a measure of treatment affordability 
as a whole, but only of medicine afford-
ability. Since medicines account for a 
large portion of total treatment costs in 
low- and middle-income countries,9–12 
their cost is largely indicative of people’s 
ability to afford the treatment for specific 
diseases.
Another limitation is the choice of 
the thresholds used to define impoverish-
ment and catastrophic expenditure. Such 
a choice obviously influences the afford-
ability outcomes and cannot be unam-
biguously defined. The impoverishment 
method calls for defining a threshold 
below which people are considered to be 
impoverished. Although the thresholds 
used in our study are well accepted and 
commonly applied, even in the context of 
global development initiatives, including 
the Millennium Development Goals,41 
they are ultimately based on normative 
choices regarding minimum human 
requirements in areas such as housing 
and nutrition. Many countries have de-
fined their own poverty lines and these 
could also be used in this context, since 
the absolute threshold required for use 
of the impoverishment method should 
reflect the living standards in a given 
country. The thresholds employed for 
the catastrophic method are even more 
arbitrary. We therefore recommend us-
ing a range of thresholds when applying 
the catastrophic method. The level of 
analysis should also be considered when 
setting a threshold. For instance, the rel-
evant threshold may be set lower when 
assessing the affordability of individual 
medicines rather than total health-care 
expenditures. It is important that such 
choices be explicitly justified within 
studies.
The methods proposed in this paper 
allow for a more accurate estimate of 
affordability than the LPGW method 
when reliable aggregated expenditure 
data are available to mitigate the data 
effect. The methodological effect is neg-
ligibly small when macro methods are 
used, but the data effect can be sizable. 
Thus, using the WDI’s household final 
consumption expenditures as a proxy 
for expenditures at the aggregate level 
can be useful in identifying trends in the 
affordability of medicines or other com-
modities, but the absolute numbers have 
to be interpreted with caution. If better 
aggregated data (i.e. data that is closer to 
estimates from household surveys) are 
available, the proposed macro methods 
allow for quite reliable affordability 
estimates. We have for example used 
aggregated spending indicators from 
India’s Planning Commission web site42 
for Maharashtra state and confirmed 
affordability estimates to be very close 
to those based on household NSS data. 
(The results are available from the cor-
responding author upon request.)
A critique to the LPGW approach is 
that it may tend to overestimate afford-
ability, as in many countries a substantial 
proportion of the population earns less 
than the LPGW. This was confirmed by 
our data. Using the micro method with 
micro data we find 95.5% of the popula-
tion earns less than the LPGW in Indo-
nesia, in India this percentage is 99.8%. 
In Indonesia, the average LPGW wage 
was IDR 20 700 a day in 2004 (WHO/
HAI survey). In India, the average LPGW 
wage over the seven WHO/HAI surveys 
was INR 133.81 (range: 120.00–143.93).
The two methods described herein, 
which are conceptually different, present 
ample opportunities for future research. 
Which method should be applied de-
pends to a great extent on a particular 
country’s economic situation. When a 
large percentage of the population has a 
pre-payment income below the poverty 
line, the impoverishment method is use-
ful only if this percentage is known. On 
the other hand, the catastrophic method 
does not capture to what extent, if at all, 
the “catastrophic” payments on medi-
cines actually cause poverty and hard-
ship. Very rich households can spend 
a “catastrophic” percentage of their 
income on medicines without experi-
encing any financial difficulties. Again, 
affordability is a vague concept and its 
measurement requires some normative 
assumptions. This paper’s purpose was 
not to impose particular assumptions, 
but rather to propose measurement tools 
that can be easily applied in settings 
where detailed household-level data are 
limited or unavailable to operationalize 
the concept of affordability, whether 
they are applied to medicines or to other 
health commodities. Such methods 
are particularly helpful in comparing 
affordability across countries or over 
time and their use can provide policy-
makers with useful insights into people’s 
purchasing power in relation to the cost 
of medicines. ■
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صخلم
ةيودلأا لىع قيبطتلا :قافنلإا لمتح لىع ةردقلل ليمعلا سايقلا
 لمتح  لىع  ةردقلا  سايقل  ينتيلمع  ينتقيرط  ةغايص  ضرغلا
.ةيمانلا نادلبلا في ةيودلأا لىع قافنلإا
 ةقيرطو ةيثراكلا ةقيرطلا - ناتحترقلما ناتقيرطلا دمتعت ةقيرطلا
 اهيلإ لوصولا لهسي يتلا ةع َّمجلما قافنلإا تانايب لىع - راقفلإا
 .قلطلما  لخدلا  ىوتسمو  دلبلا  لخد  عيزوت  نابسلحا  في  عضتو
 مهدراوم ضفخنتس نيذلا ناكسلا ةبسن ةيثراكلا ةقيرطلا سيقت
 ةقيرط  ردقت  مانيب  ؛ينعم  ءاود  لىع  قافنلإا  ةجيتن  يثراك  لكشب
 ةجيتن  رقفلا  طخ  تتح  اهعفد  متيس  يتلا  ناكسلا  ةبسن  راقفلإا
 ةردقلا  باسحب ينتقيرطلا  ينتاه حاضيإ  متيو .ينعم ءاود ءاشر
 ةداضلما يرقاقعلا دحأ ،ديملاكنيبيلغ راقع لىع قافنلإا لمتح لىع
 جئاتنلا  نم  ققحتلا  متو  .ايسينودنإو  دنلها  في  ،يركسلا  ءادل
 تانايبلا  مادختساب  اهيلع  لوصلحا  مت  يتلا  جئاتنلاب  اهتنراقمب
.ايسينودنإو دنلها في ةيلئاعلا ةيئزلجا
 ناتقيرطلا  رفوت  ،ةقيقدلا  ةع َّمجلما  تانايبلا  ةحاتإ  دنع  جئاتنلا
 ةيرثو  ةقيقد  تاريدقت  لىع  لوصحلل  ةيلمع  ةليسو  ناتحترقلما
 ماهجئاتن  هباشتتو  .قافنلإا  لمتح  لىع  ةردقلا  لوح  تامولعلماب
 مادختساب  اهيلع  لوصلحا  مت  يتلا  كلت  عم  ةياغلل  يربك  لكشب
 .نادلبلا برع اهتنراقم لهسي ماك ةيلئاعلا ةيئزلجا تانايبلا ليلتح
 – راقفلإا ةقيرطو ةيثراكلا ةقيرطلا رفوت نأ نكملما نم جاتنتسلاا
 قافنلإا لمتح لىع ةردقلل اًبسانم اًريدقت – ةيلكلا تانايبلا لىع ًءانب
 ليئاعلا  ىوتسلما  لىع ةيئزلجا تانايبلا  رفاوت  مدع دنع ءاودلا  لىع
 رفاوت لىع ماتهدئاف دمتعتو .اًروطت رثكأ تاسارد ءارجلإ ةمزلالا
.ةقيقدلا ةع َّمجلما تانايبلا
Résumé
Mesure pratique de l’abordabilité: une application aux médicaments
Objectif Développer deux méthodes pratiques permettant de 
mesurer l’abordabilité des médicaments dans les pays en voie de 
développement.
Méthodes Les méthodes proposées (la méthode catastrophique 
et la méthode de l’appauvrissement) reposent sur des données de 
dépenses agrégées facilement accessibles et prennent en compte 
la répartition des revenus d’un pays ainsi que le niveau de revenu 
absolu. La méthode catastrophique quantifie la proportion de 
la population dont les ressources seraient réduites de manière 
catastrophique par une dépense pour un médicament donné. La 
méthode de l’appauvrissement estime la proportion de la population 
qui passerait sous le seuil de pauvreté en achetant un médicament 
donné. Ces méthodes sont illustrées par le calcul de l’abordabilité 
de la glibenclamide, un médicament antidiabétique, en Inde et en 
Indonésie.
Résultats Lorsque des données agrégées précises sont disponibles, 
les méthodes proposées offrent un moyen pratique d’obtenir des 
estimations informatives et précises sur l’abordabilité. Leurs résultats 
sont très similaires à ceux obtenus par l’analyse des micro-données 
des ménages et sont facilement comparables d’un pays à l’autre.
Conclusion La méthode catastrophique et la méthode de 
l’appauvrissement, basées sur les macro-données, peuvent offrir une 
estimation convenable de l’abordabilité des médicaments lorsque les 
micro-données des ménages nécessaires à des études plus poussées 
ne sont pas disponibles. Leur utilité dépend de la disponibilité de 
données agrégées précises. 
Резюме
Практический метод оценки доступности: применительно к лекарственным средствам
Цель Разработать два практических метода определения 
доступности лекарственных средств в развивающихся странах.
Методы Предлагаемые методы – катастрофических расходов и 
обнищания – основываются на легко доступных обобщенных данных 
о расходах и учитывают распределение доходов внутри страны и 
абсолютный уровень доходов. В методе катастрофических расходов 
рассчитывается доля населения, чьи ресурсы катастрофически 
сократятся при наличии расходов на данное лекарственное 
средство; метод обнищания оценивает долю населения, 
которая будет вытолкнута за черту бедности в результате 
покупки данного лекарства. Данные методы иллюстрируются 
расчетом доступности в Индии и Индонезии глибенкламида, 
противодиабетического препарата. Результаты исследований 
были проверены путем сопоставления их с результатами, 
полученными с использованием микроэкономических 
показателей домохозяйств в Индии и Индонезии.
摘要
实用的购买力测量方法：药物上的应用
目的 制定两种测量发展中国家药物购买力的实用方法。
方法 所提出的灾化法和贫化法依赖于易于获得的汇总支出
数据并将一个国家的收入分配情况和收入绝对水平考虑在
内。灾化法量化因购买特定药物而导致其资源灾难性地减
少的人口比例；贫化法估算出因努力获得特定药物而陷入
贫困线之下的人口比例。通过计算印度和印度尼西亚优降
糖及抗糖尿病药物的购买力对这两种方法进行说明。其结
果通过与印度和印度尼西亚采用家庭微观数据获得的结果
相比较得到验证。
结果 在能够获得准确汇总数据的情况下，所提出的方法为
翔实且准确地评估购买力提供了切实可行的途径。其结果
与采用家庭微观数据分析所得结果非常相似，也易于进行
不同国家比较。
结论 在无法获取进行更为精细的研究所需的家庭层面的微
观数据时，基于宏观数据的灾化法和贫化法能够恰当预估
药物购买力。其有效性取决于准确汇总数据的可用性。 
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Resumen
Medición práctica de la asequibilidad: aplicación a los medicamentos
Objetivo Desarrollar dos métodos prácticos para medir la asequibilidad 
de los medicamentos en los países en vías de desarrollo.
Métodos Los métodos propuestos (métodos para medir los 
gastos catastróficos y el empobrecimiento) se basan en unos datos 
agregados fácilmente accesibles sobre el gasto y tienen en cuenta 
tanto la distribución de los ingresos del país como el nivel absoluto de 
ingresos. El método de gasto catastrófico cuantifica la proporción de la 
población cuyos recursos se verían reducidos de manera catastrófica 
si tuvieran que adquirir un medicamento determinado. El método del 
empobrecimiento calcula la proporción de la población que pasaría 
a encontrarse por debajo del umbral de la pobreza si comprara un 
medicamento determinado. Estos métodos se demuestran calculando 
la asequibilidad de la glibenclamida, un medicamento antidiabético, 
en India e Indonesia. Los resultados se refrendaron mediante su 
comparación con los resultados obtenidos empleando los microdatos 
para India e Indonesia.
Resultados Cuando se dispone de datos agregados precisos, los 
métodos propuestos constituyen una forma práctica de obtener 
evaluaciones informativas y precisas sobre la asequibilidad. Sus 
resultados son muy similares a los obtenidos mediante los análisis de 
microdatos nacionales y resultan fáciles de comparar entre los diversos 
países. 
Conclusión Los métodos de gasto catastrófico y de empobrecimiento 
basados en macrodatos pueden ofrecer una evaluación adecuada de 
la asequibilidad de un medicamento cuando no se dispone de los 
microdatos necesarios a nivel nacional para desarrollar estudios más 
complejos. Su utilidad depende de la disponibilidad de unos datos 
agregados precisos.
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